DUNN JEFFREY W sold $369K of SIBN

DUNN JEFFREY W sold 20,000 shares of SI-BONE, Inc. (SIBN) at $18.47 ($0.37M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DUNN JEFFREY W
Published Oct 5, 2026, 9:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The filing provides fresh, primary‑source data but the transaction size is modest, limiting market impact.

02

Market read

Insider sales are monitored by traders; this modest director sale may cause slight short‑term pressure on SIBN.

03

What to watch

The 10b5-1 plan indicates pre‑planned execution, reducing the informational value of the sale.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Oct 5

Background

SEC Form 4 filing discloses a director's sale of SIBN shares under a pre‑arranged trading plan.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Director Jeff Dunn sold 20,000 shares for $369,400 via a 10b5-1 plan, reducing his stake to 16,057 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A director sold a sizable block under a pre‑arranged plan; such sales often prompt short‑term selling pressure.

Market effects

Minimal impact on the orthopedics device sector.

No broader regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be routine and unrelated to fundamentals, so price impact may be negligible.

Key entities

  • SI‑BONE, Inc.

    Medical device maker specializing in spinal implants.

  • Jeff Dunn

    Director of SI‑BONE, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.